Vamsidhar Velcheti

Oct 3, 2024 | mdpi.com | Vivek Podder |Kim Margolin |Vamsidhar Velcheti |Tulika Ranjan

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Nov 15, 2023 | onclive.com | Vamsidhar Velcheti

Vamsidhar Velcheti, MD, professor, Department of Medicine, New York University (NYU) Grossman School of Medicine, director, thoracic medical oncology, NYU Langone Perlmutter Cancer Center, discusses the significance of the FDA approval of the ROS1 TKI repotrectinib (Augtyro) in patients with ROS1-positive metastatic non–small cell lung cancer (NSCLC). On November 15, 2023, the FDA approved repotrectinib for patients with locally advanced or metastatic NSCLC harboring ROS1 fusions.

Jun 12, 2023 | social.cn1699.com | Vamsidhar Velcheti

Source/Disclosures Published by: Source: Besse B, et al. Abstract 9013. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Besse reports research funding to his institution from AbbVie, Amgen, Aptitude Health, AstraZeneca, Chugai Pharma, Daiichi Sankyo, Eisai, Genmab, Genzyme, Ipsen, Janssen Oncology, MSD Oncology, Roche/Genentech, Sanofi, Taiho Pharmaceutical and other companies. Please see the abstract for all other researchers’ relevant financial disclosures.